Simon Barry J. 4

What Happened
Simon Barry, a director of ImmunityBio, sold a total of 151,967 shares on January 20, 2026, in two open-market transactions. He disposed of 76,967 shares at $6.54 each (proceeds $503,364) and 75,000 shares at a weighted-average price of $7.88 each (proceeds $590,933), for aggregate proceeds of approximately $1,094,297. These transactions are sales (S) reported on a Form 4 filed January 21, 2026.

Key Details

• Transaction date: 2026-01-20; Form 4 filed: 2026-01-21 (no late filing indicated)
• Sales: 76,967 shares @ $6.54 = $503,364; 75,000 shares @ weighted avg $7.88 (range $7.87–$7.8950) = $590,933
• Total shares sold: 151,967; total proceeds ≈ $1.09 million
• Footnotes: (F1) Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Sept 4, 2024. (F2) Weighted-average price disclosure for the 75,000-share block; reporting person can provide per-price breakdown on request.
• Exhibit: Exhibit 24 (Power of Attorney) attached to filing
• Shares owned after transaction: Not provided in the excerpt; see the full Form 4 for post-transaction holdings.

Context
Trades executed under a Rule 10b5-1 plan are pre-scheduled and commonly viewed as routine, limiting inference of trading on material nonpublic information. For retail investors, purchases are generally more informative than sales; here, these are director-initiated, pre-planned sales totaling about $1.09M. For complete ownership details and timing context, review the full Form 4 on the SEC EDGAR system (Accession 0001647994-26-000002).